{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:46:00Z","timestamp":1770468360854,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012379","name":"Anton and Petra Ehrmann-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck Darmstadt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.msard.2024.105812","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T06:22:35Z","timestamp":1723270955000},"page":"105812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Posevitz-Fejf\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chudecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Cepek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Reifschneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris-Katharina","family":"Penner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105812_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.msard.2024.105812_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2024.105812_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103385","article-title":"Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis","volume":"57","author":"Brochet","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2024.105812_bib0004","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1177\/13524585231205962","article-title":"Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study","volume":"29","author":"Brochet","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105812_bib0005","unstructured":"Cohen J., 1988. Statistical power analysis for the behavioral sciences."},{"issue":"4","key":"10.1016\/j.msard.2024.105812_bib0006","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105812_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","article-title":"Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study","volume":"17","author":"Coyle","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2024.105812_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185766","article-title":"Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)","volume":"12","author":"Fern\u00e1ndez","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.msard.2024.105812_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2024.105812_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105812_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105812_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/PPA.S41992","article-title":"A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod","volume":"7","author":"Hanson","year":"2013","journal-title":"Patient Prefer. Adherence"},{"issue":"2","key":"10.1016\/j.msard.2024.105812_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2022-000315","article-title":"Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data","volume":"4","author":"Hardy","year":"2022","journal-title":"BMJ Neurol. Open"},{"issue":"4","key":"10.1016\/j.msard.2024.105812_bib0015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40120-023-00497-2","article-title":"Multicentre observational study of treatment satisfaction with cladribine tablets in the management of relapsing multiple sclerosis in the Arabian Gulf: the CLUE study","volume":"12","author":"Inshasi","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2024.105812_bib0008","unstructured":"EMA summary of product charateristics: Mavenclad\u00ae (cladribine tablets). https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/mavenclad-epar-product-information_en.pdf. (accessed 22 Jun 2023)."},{"key":"10.1016\/j.msard.2024.105812_bib0016","unstructured":"Krankheitsbezogenes Kompetenznetz Multiple Sklerose, 2023. Qualit\u00e4tshandbuch MS \/NMOSD \/ MOGAD. https:\/\/ms-qualitaetshandbuch.de\/ (accessed 22 June 2023)."},{"key":"10.1016\/j.msard.2024.105812_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2147\/PPA.S307987","article-title":"Subcutaneous interferon beta therapy in multiple sclerosis patients - characterization of injection site reactions and flu-like symptoms in a daily practice setting - results from the non-interventional study PERFECT","volume":"15","author":"Kukowski","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2024.105812_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S8230","article-title":"Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence","volume":"4","author":"Patti","year":"2010","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2024.105812_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103670","article-title":"A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab","volume":"59","author":"R\u00e4uber","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105812_bib0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/PPA.S248272","article-title":"Health-related quality of life and the relationship to treatment satisfaction in patients with multiple sclerosis: insights from a large observational study","volume":"14","author":"Schriefer","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2024.105812_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105812_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.msard.2024.105812_bib0023","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/1352458516657441","article-title":"Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?","volume":"23","author":"Vermersch","year":"2017","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T07:56:23Z","timestamp":1726386983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":23,"alternative-id":["S2211034824003894"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105812","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105812"}}